Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1988-05-18
1991-02-12
Lee, Mary C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
548337, 548317, A61K 31415, C07D23366, C07D23330
Patent
active
049924591
ABSTRACT:
Potent DBH inhibitors having the formula ##STR1## can be used to inhibit DBH activity in mammals.
REFERENCES:
patent: 3488423 (1979-01-01), Doebel et al.
patent: 3915980 (1975-10-01), Gebert et al.
patent: 4340738 (1982-07-01), Sipido
patent: 4487761 (1984-12-01), Cole et al.
patent: 4532331 (1985-07-01), Frazee et al.
patent: 4798843 (1989-01-01), Kruse
Iverson et al., Acta Chem. Scand., 21:279-285, (1967).
Fuller et al., Adv. Enzyme Regul., 15;267-281, (1976).
Runti et al., Il. Farmaco Ed. Sc., 36:260-268, (1980).
Goldstein, Pharmacol. Rev., 18:77-82, (1966).
Gebert et al., Chemical Abstracts, 72:39275e, (1970).
Hidaka et al., Mol. Pharmacol., 9:172-177, (1973).
Finkelstein Joseph A.
Frazee James S.
Kaiser Carl
Kruse Lawrence I.
Leonard Thomas B.
Lee Mary C.
Lentz Edward T.
McCarthy Mary E.
SmithKline Beecham Corporation
Suter Stuart R.
LandOfFree
Dopamine-.beta.-hydroxylase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dopamine-.beta.-hydroxylase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dopamine-.beta.-hydroxylase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-20907